Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CDK-002 |
Synonyms | |
Therapy Description |
CDK-002 consists of exosomes containing a STING agonist and expressing PTGFRN (CD315), which may bind to antigen-presenting cells and activate innate immune response (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CDK-002 | CDK 002|CDK002 | STING1 Agonist 19 | CDK-002 consists of exosomes containing a STING agonist and expressing PTGFRN (CD315), which may bind to antigen-presenting cells and activate innate immune response (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04592484 | Phase Ib/II | CDK-002 | A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors | Completed | USA | GBR | 0 |